XML 61 R42.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of Significant Accounting Policies - Fair Value Measurements (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Dec. 12, 2023
Oct. 10, 2023
Jun. 20, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and cash equivalents, fair value disclosure $ 79,167 $ 147,478      
Assets measured at fair value 2,213 5,624      
Assets, fair value disclosure 81,380 153,102      
Contingent consideration 43,939 54,457      
Liabilities, fair value disclosure 43,939 54,457      
Drug Interaction Solutions University of Washington (DIDB)          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent consideration 132        
Drug Interaction Solutions University of Washington (DIDB) | Revenue Target          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent consideration         $ 790
Formedix          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent consideration 0 3,696   $ 5,161  
Formedix | Revenue Target          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent consideration       $ 4,380  
Applied Biomath          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent consideration 0 5,380      
Applied Biomath | Revenue Target          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent consideration     $ 5,357    
Vyasa Analytics, LLC | Revenue Target          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Contingent consideration 19,813        
LEVEL 1          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and cash equivalents, fair value disclosure 79,167 147,478      
Assets measured at fair value 0 0      
Assets, fair value disclosure 79,167 147,478      
Contingent consideration 0 0      
Liabilities, fair value disclosure 0 0      
LEVEL 2          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and cash equivalents, fair value disclosure 0 0      
Assets measured at fair value 2,213 5,624      
Assets, fair value disclosure 2,213 5,624      
Contingent consideration 0 0      
Liabilities, fair value disclosure 0 0      
LEVEL 3          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and cash equivalents, fair value disclosure 0 0      
Assets measured at fair value 0 0      
Assets, fair value disclosure 0 0      
Contingent consideration 43,939 54,457      
Liabilities, fair value disclosure $ 43,939 $ 54,457